A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemia

Blood Cancer Journal

Volumn 4, Issue 8, 2014, Pages

  Samuels, A L ^a   Beesley, A H ^a   Yadav, B D ^b   Papa, R A ^b   Sutton, R ^b   Anderson, D ^a   Marshall, G M ^c   Cole, C H ^d   Kees, U R ^a   Lock, R B ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c SYDNEY CHILDREN'S HOSPITAL   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CHOLESTEROL; DAUNORUBICIN; DEXAMETHASONE; HYPOCHOLESTEROLEMIC AGENT; SIMVASTATIN; VINCRISTINE;

ADOLESCENT; ANIMAL; CHILD; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; INFANT; MALE; METABOLISM; MOUSE; NEOPLASMS, EXPERIMENTAL; NUDE MOUSE; PATHOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; PROCEDURES; SCID MOUSE; TUMOR CELL LINE;

ADOLESCENT; ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; CHOLESTEROL; DAUNORUBICIN; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; INFANT; MALE; MICE; MICE, NUDE; MICE, SCID; NEOPLASMS, EXPERIMENTAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SIMVASTATIN; VINCRISTINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84906856779     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2014.52     Document Type: Article

References (47)

1. Kaatsch P. Epidemiology of childhood cancer. Cancer Treat Rev 2010; 36: 277-285.p
2. Lo Nigro L. Biology of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2013; 35: 245-252.p
3. Pui CH, Mullighan CG, Evans WE, Relling MV. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood 2012; 120: 1165-1174.p
4. Bhadri VA, Trahair TN, Lock RB. Glucocorticoid resistance in paediatric acute lymphoblastic leukaemia. J Paediatr Child Health 2012; 48: 634-640.p
5. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354: 166-178.p
6. Dordelmann M, Reiter A, Borkhardt A, Ludwig WD, Gotz N, Viehmann S et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 1999; 94: 1209-1217.p
7. Den Boer ML, Harms DO, Pieters R, Kazemier KM, Gobel U, Korholz D et al. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol 2003; 21: 3262-3268.p
8. Kaspers GJ, Veerman AJ, Pieters R, Van Zantwijk CH, Smets LA, Van Wering ER et al. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 1997; 90: 2723-2729.p
9. Locatelli F, Schrappe M, Bernardo ME, Rutella S. How I treat relapsed childhood acute lymphoblastic leukemia. Blood 2012; 120: 2807-2816.p
10. Marshall GM, Dalla Pozza L, Sutton R, Ng A, de Groot-Kruseman HA, van der Velden VH et al. High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation. Leukemia 2013; 27: 1497-1503.p
11. Bailey LC, Lange BJ, Rheingold SR, Bunin NJ. Bone-marrow relapse in paediatric acute lymphoblastic leukaemia. Lancet Oncol 2008; 9: 873-883.p
12. Kaspers GJ, Wijnands JJ, Hartmann R, Huismans L, Loonen AH, Stackelberg A et al. Immunophenotypic cell lineage and in vitro cellular drug resistance in childhood relapsed acute lymphoblastic leukaemia. Eur J Cancer 2005; 41: 1300-1303.p
13. Klumper E, Pieters R, Veerman AJ, Huismans DR, Loonen AH, Hahlen K et al. In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood 1995; 86: 3861-3868.p
14. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 2012; 9: 338-350.p
15. Macor P, Secco E, Zorzet S, Tripodo C, Celeghini C, Tedesco F. An update on the xenograft and mouse models suitable for investigating new therapeutic compounds for the treatment of B-cell malignancies. Curr Pharm Des 2008; 14: 2023-2039.p
16. Lock RB, Liem N, Farnsworth ML, Milross CG, Xue C, Tajbakhsh M et al. The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse. Blood 2002; 99: 4100-4108.p
17. Liem NL, Papa RA, Milross CG, Schmid MA, Tajbakhsh M, Choi S et al. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood 2004; 103: 3905-3914.p
18. Bhadri VA, Cowley MJ, Kaplan W, Trahair TN, Lock RB. Evaluation of the NOD/SCID xenograft model for glucocorticoid-regulated gene expression in childhood B-cell precursor acute lymphoblastic leukemia. BMC Genomics 2011; 12: 565.p
19. Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer 2007; 49: 928-940.p
20. Wei G, Twomey D, Lamb J, Schlis K, Agarwal J, Stam RW et al. Gene expressionbased chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 2006; 10: 349-351.p
21. Qu XA, Rajpal DK. Applications of Connectivity Map in drug discovery and development. Drug Discov Today 2012; 17: 1289-1298.p
22. Wong WW, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002; 16: 508-519.p
23. Borisy AA, Elliott PJ, Hurst NW, Lee MS, Lehar J, Price ER et al. Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci U S A 2003; 100: 7977-7982.p
24. Winter GE, Rix U, Carlson SM, Gleixner KV, Grebien F, Gridling M et al. Systemspharmacology dissection of a drug synergy in imatinib-resistant CML. Nat Chem Biol 2013; 8: 905-912.p
25. Szymanska B, Wilczynska-Kalak U, Kang MH, Liem NLM, Carol H, Boehm I et al. Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts. PLoS ONE 2012; 7: e33894.p
26. Beesley AH, Firth MJ, Ford J, Weller RE, Freitas JR, Perera KU et al. Glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia is associated with a proliferative metabolism. Br J Cancer 2009; 100: 1926-1936.p
27. Beesley AH, Rampellini JL, Palmer ML, Heng JY, Samuels AL, Firth MJ et al. Influence of wild-type MLL on glucocorticoid sensitivity and response to DNAdamage in pediatric acute lymphoblastic leukemia. Mol Cancer 2010; 9: 284.p
28. Beesley AH, Firth MJ, Anderson D, Samuels AL, Ford J, Kees UR. Drug-gene modeling in pediatric T-cell acute lymphoblastic leukemia highlights importance of 6-mercaptopurine for outcome. Cancer Res 2013; 73: 2749-2759.p
29. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006; 313: 1929-1935.p
30. Konopleva M, Andreeff M. Role of peroxisome proliferator-activated receptorgamma in hematologic malignancies. Curr Opin Hematol 2002; 9: 294-302.p
31. Koeffler HP. Peroxisome proliferator-activated receptor gamma and cancers. Clin Cancer Res 2003; 9: 1-9.p
32. Hindler K, Cleeland CS, Rivera E. Collard CD. The role of statins in cancer therapy. Oncologist 2006; 11: 306-315.p
33. Andela VB, Pirri M, Schwarz EM, Puzas EJ, O'Keefe RJ, Rosenblatt JD et al. The mevalonate synthesis pathway as a therapeutic target in cancer. Clin Orthop Relat Res 2003, S59-S66.p
34. Infante E, Heasman SJ, Ridley AJ. Statins inhibit T-acute lymphoblastic leukemia cell adhesion and migration through Rap1b. J Leukocyte Biol 2011; 89: 577-586.p
35. Li HY, Appelbaum FR, Willman CL, Zager RA, Banker DE. Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood 2003; 101: 3628-3634.p
36. Calabro A, Tai J, Allen SL, Budman DR. In-vitro synergism of m-TOR inhibitors, statins, and classical chemotherapy: potential implications in acute leukemia. Anticancer Drugs 2008; 19: 705-712.p
37. Andela VB, Altuwaijri S, Wood J, Rosier RN. Inhibition of beta-oxidative respiration is a therapeutic window associated with the cancer chemo-preventive activity of PPARgamma agonists. FEBS Lett 2005; 579: 1765-1769.p
38. Samudio I, Harmancey R, Fiegl M, Kantarjian H, Konopleva M, Korchin B et al. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest 2010; 120: 142-156.p
39. Bachmann PS, Piazza RG, Janes ME, Wong NC, Davies C, Mogavero A et al. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. Blood 2010; 116: 3013-3022.p
40. Anderson K, Lutz C, van Delft FW, Bateman CM, Guo Y, Colman SM et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011; 469: 356-361.p
41. Clappier E, Gerby B, Sigaux F, Delord M, Touzri F, Hernandez L et al. Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J Exp Med 2011; 208: 653-661.p
42. Choi S, Henderson MJ, Kwan E, Beesley AH, Sutton R, Bahar AY et al. Relapse in children with acute lymphoblastic leukemia involving selection of a preexisting drug-resistant subclone. Blood 2007; 110: 632-639.p
43. Kawedia JD, Kaste SC, Pei D, Panetta JC, Cai X, Cheng C et al. Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood 2011; 117: 2340-2347.p
44. Chan KKW, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res 2003; 9: 10-19.p
45. van de Steeg E, Kleemann R, Jansen HT, van Duyvenvoorde W, Offerman EH, Wortelboer HM et al. Combined analysis of pharmacokinetic and efficacy data of preclinical studies with statins markedly improves translation of drug efficacy to human trials. J Pharmacol Exp Ther 2013; 347: 635-644.p
46. Sanda T, Li X, Gutierrez A, Ahn Y, Neuberg DS, O'Neil J et al. Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia. Blood 2010; 115: 1735-1745.p
47. Hartwell KA, Miller PG, Mukherjee S, Kahn AR, Stewart AL, Logan DJ et al. Niche-based screening identifies small-molecule inhibitors of leukemia stem cells. Nat Chem Biol 2013; 9: 840-848.p